BioLargo's Odor-No-More Products Approved to Sell Through GSA Advantage and VA Schedule

SANTA ANA, CA--(Marketwired - Mar 7, 2016) - BioLargo, Inc. (OTCQB: BLGO) announced today that two product lines (consisting of 9 SKUs) of its Nature's Best Science products were awarded a five year U.S. General Services Administration (GSA) supply contract, under schedule 65IIA for medical equipment and supplies. The award opens up an important selling channel for the company's current and future products.

The GSA Schedules program is the premier acquisition vehicle in government, with approximately $50 Billion a year in spending. The GSA's medical equipment and supplies Schedule 65IIA Contract provides federal agencies with medical supplies for a wide variety of uses such as public safety, medical research, and laboratory diagnostics. Winning a GSA supplier contract is a lengthy process averaging 12-15 months. Approval required BioLargo and its distribution partner, Downeast Logistics, establish the products met quality manufacturing standards, and that they had delivery capabilities, a minimum level of prior sales to the government and operations history, and a satisfactory Dunn & Bradstreet rating. The GSA contract awarded allows for the sale of specific Odor-No-More products for a period of five years, subject to renewal of up to 20 years. The supplier contract opens the door for sales through "GSA Advantage," the online shopping and ordering system that provides government agencies access to thousands of contractors and millions of supplies (products) and services.

"Obtaining status on the GSA schedules is a significant accomplishment, and provides us significant opportunity to sell to the U.S. government," said Odor-No-More President, Joe Provenzano. "All of the products that we currently offer the Defense Logistics Agency (DLA) through DIBBS and Military Medical Facilities (MMF) through the DAPA will now be available through GSA Advantage and the VA FSS Schedule."

Dennis P. Calvert, President and CEO of BioLargo, added, "Securing this GSA award is the culmination of more than 18 months of work. Now that we've been accepted into this selling channel, we intend to add more products, including those from our Clyra Medical subsidiary when they are ready for market."

About BioLargo, Inc.

BioLargo, Inc. (BLGO) makes life better by delivering sustainable technology-based products that help solve some of the most widespread problems threatening the world's supply of water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter -- a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. It is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry and is named the Technology Innovation Leader in the water treatment market by Frost & Sullivan. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project, now being commercialized under a license to Clarion Water, Inc. BioLargo's subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, military supply and consumer markets, including the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management.

Safe Harbor Statement

The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K.